November 12: Essential Medicine Supply Management Moves from "Request" to "Obligation"
Korea's amended Pharmaceutical Affairs Act takes effect on November 12, 2026, and the government has pre-announced a follow-up amendment to its Enforcement Decree. After several years of repeated shortages of cold medicines, fever reducers, and pediatric drugs, the government's policy of directly managing the supply chain for national essential medicines is now written into law.
For manufacturers and importers, these are the changes that matter most:
How This Differs from the Existing Supply Discontinuation Report
Korea already has a supply discontinuation reporting system. It covers products such as drugs designated to prevent market withdrawal, orphan drugs, ingredients with two or fewer products on the market, products with a market share of 50% or more, the top 100 ingredients by national health insurance claims, and national essential medicines. Discontinuing production, import, or supply of these products generally requires a report to the MFDS 180 days in advance. Under the penalty schedule reported in the press, late reports trigger manufacturing suspensions that escalate from 7 days for a first violation to 3 months for a fourth. Confirm the current deadlines and scope against the Enforcement Rule and the relevant notice.
The key shift is that the government now wants visibility at the reduction stage, not just at discontinuation. Cutting volumes without halting supply entirely may now trigger a reporting duty, which moves the reporting point much earlier. Penalties for breaching the new duty should only be described once the final provisions and subordinate regulations are published.
Where Small Pharma Companies Are Most Likely to Slip
Building an Internal Reporting System
Turning Risk into Opportunity: Policy Support for Supply Stability
Tighter supply oversight is a burden, but companies that keep supply stable also have a chance to benefit from policy support. It is worth checking whether your products qualify for existing programs, such as cost compensation for drugs designated to prevent market withdrawal or the public contract manufacturing network for essential medicines. If you respond with process improvements or more diverse API sourcing instead of cutting output, look into manufacturing innovation and supply chain stabilization grants as well. Eligibility differs by program, so check each call for applications.
How KITIM Can Help
The new rules take effect in less than a month. Now is the time to check whether your products are covered and whether your reporting process would actually work. Contact the KITIM consulting team for step-by-step support, from a portfolio review to a working reporting system.